GlaxoSmithKline Pharmaceuticals (BOM:500660) Debt-to-Equity : 0.01 (As of Mar. 2024)

View and export this data going back to 1991. Start your Free Trial

What is GlaxoSmithKline Pharmaceuticals Debt-to-Equity?

GlaxoSmithKline Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₹122 Mil. GlaxoSmithKline Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₹65 Mil. GlaxoSmithKline Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Mar. 2024 was ₹17,776 Mil. GlaxoSmithKline Pharmaceuticals's debt to equity for the quarter that ended in Mar. 2024 was 0.01.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for GlaxoSmithKline Pharmaceuticals's Debt-to-Equity or its related term are showing as below:

BOM:500660' s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.01 Max: 0.02
Current: 0.01

During the past 13 years, the highest Debt-to-Equity Ratio of GlaxoSmithKline Pharmaceuticals was 0.02. The lowest was 0.00. And the median was 0.01.

BOM:500660's Debt-to-Equity is ranked better than
99.88% of 842 companies
in the Drug Manufacturers industry
Industry Median: 0.3 vs BOM:500660: 0.01

GlaxoSmithKline Pharmaceuticals Debt-to-Equity Historical Data

The historical data trend for GlaxoSmithKline Pharmaceuticals's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GlaxoSmithKline Pharmaceuticals Debt-to-Equity Chart

GlaxoSmithKline Pharmaceuticals Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Debt-to-Equity

Get a 7-Day Free Trial

0.02

0.01

GlaxoSmithKline Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial															0.01	N/A	0.01	N/A	0.01

Competitive Comparison of GlaxoSmithKline Pharmaceuticals's Debt-to-Equity

For the Drug Manufacturers - General subindustry, GlaxoSmithKline Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

GlaxoSmithKline Pharmaceuticals's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, GlaxoSmithKline Pharmaceuticals's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where GlaxoSmithKline Pharmaceuticals's Debt-to-Equity falls into.

GlaxoSmithKline Pharmaceuticals Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

GlaxoSmithKline Pharmaceuticals's Debt to Equity Ratio for the fiscal year that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(121.959	+	64.691)	/	17776.397
	=	0.01

GlaxoSmithKline Pharmaceuticals's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(121.959	+	64.691)	/	17776.397
	=	0.01

GlaxoSmithKline Pharmaceuticals (BOM:500660) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

GlaxoSmithKline Pharmaceuticals Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of GlaxoSmithKline Pharmaceuticals's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

GlaxoSmithKline Pharmaceuticals (BOM:500660) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » GlaxoSmithKline Pharmaceuticals Ltd (BOM:500660) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

GLAXO:India

Address

Dr. Annie Besant Road, GSK House, Worli, Mumbai, MH, IND, 400 030

Website

https://www.gsk-india.com

GlaxoSmithKline Pharmaceuticals Ltd is an India-based subsidiary of GlaxoSmithKline plc. GSK India develops and manufactures medicines, vaccines, and consumer products. Its medicines portfolio includes prescription drugs for conditions that include asthma, infectious diseases, mental health, and digestion, as well as nonprescription nutrition and cosmetic products. Its vaccines product line includes treatments for conditions such as influenza, HPV, hepatitis, and measles. Its consumer healthcare products include Horlicks-brand packaged food and beverage powders among other retail products. The company derives most of its revenue from India.

GlaxoSmithKline Pharmaceuticals (BOM:500660) Headlines

No Headlines